Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss

Recruiting now · Phase 4

Conditions studied: Sudden Sensorineural Hearing Loss

In brief

The goal of this clinical trial is to learn which one works to treat better in patients with sudden sensorineural hearing loss, oral or intratympanic corticosteroid treatment. The main question it aims to answer is: Which corticosteroid treatment is more effective in patients with sudden sensorineural hearing loss, oral or intratympanic? * In our study, it was planned to divide the treatment schemes compared into two groups. Group 1 included patients who received oral methylprednisolone treatment daily for 2 weeks (48 mg for the first 7 days, 32 mg for the following 2 days, 16 mg for the 2 days, and 8 mg for the last 3 days). Group 2 included patients who received intratympanic 8 mg/2 ml dexamethasone every other day, totally 4 doses. * Visit the clinic after diagnose in first week, second week, first month and second month for checkups and tests ( temporal MR, odimetric results)

Key facts

Study ID: NCT06968507
Run by: Dr. Lutfi Kirdar Kartal Training and Research Hospital
People needed: 214
Starts: 2025-05-20
Expected to finish: 2028-09-10
Last updated by the study team: 2025-05-13

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

18 years of age and older
Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less
Affected side PTA (500-100-2000-4000hz) should be over 50dB
Affected side should be at least 30dB lower than healthy side in 3 frequencies
Hearing should be symmetrical according to patient's statement before sensorineural hearing loss
If used, steroid use should be less than 10 days
Cerebellar and vestibular examination should be normal

You may not qualify if…

Having a history of hearing-related surgery other than a ventilation tube
Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or cholesteatoma, otosclerosis
Being under 18 or over 80
Having a history of physical-barotrauma
Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss
Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with atherosclerotic disease, serious psychiatric patients, those receiving chemotherapy, radiotherapy or immunosuppressant treatment, pancreatitis patients, HIV, hepatitis C and B patients, those with chronic renal failure, substance abusers, those with active herpetic lesions, severe osteoporosis patients, those with hearing loss within 4 weeks after general anesthesia, those with a history of head and neck cancer.

Where it is running

Dr Lütfi Kırdar City Hospital — Istanbul, Kartal, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.